Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients

Inclusion Criteria:

• Type I or II diabetes patients aged 18 to 75 years (including 18 and 75 years),regardless of gender;

• Stable peritoneal dialysis patients who have undergone peritoneal dialysis treatmentfor ≥ 3 months;

• Use 3-5 bags of peritoneal dialysis solution daily;

• 6.0%<glycated hemoglobin (HbA1c) level ≤ 8.5%;

• 90g/L ≤ Hemoglobin concentration ≤ 130g/L

• Stable use of erythropoietin and rosuvastatin;

• The fluctuation of carbohydrate energy supply ratio in the first 3 months beforeenrollment is less than 15%;

• Not using amino acid (15) peritoneal dialysis solution for the first 3 months beforeenrollment;

• Within the past month, the patient's prescription for hypoglycemic drugs has notbeen adjusted;

• Within the past month, the patient's dietary structure and food intake have remainedstable.

Exclusion Criteria:

• Peritonitis has occurred within the past 3 months;

• Use Acodextrin peritoneal dialysis solution;

• Contraindications for the presence of amino acids (15) in peritoneal dialysis fluid:

1. Individuals allergic to any component of amino acid (15) peritoneal dialysisfluid;

2. Serum urea level>38 mmol/l;

3. Metabolic acidosis (CO2 binding capacity<22mmol/L);

4. Severe hypokalemia (blood potassium<2.5mmol/L);

5. Various congenital amino acid metabolism abnormalities;

6. Liver dysfunction (alanine aminotransferase levels exceeding 2.5 times theupper limit of normal);

• Combined hemoglobinopathies: such as thalassemia, sickle cell disease, etc;

• It is expected that kidney transplantation may be accepted during the trial period;

• Participated in other clinical studies.